Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Insulin Resistance Intervention After Stroke Trial
Insulin Resistance Intervention After Stroke (IRIS) Trial
Status: Enrolling
Updated:  1/6/2016
Flinders Medical Centre
mi
from 43215
Bedford Park,
Insulin Resistance Intervention After Stroke Trial
Insulin Resistance Intervention After Stroke (IRIS) Trial
Status: Enrolling
Updated: 1/6/2016
Flinders Medical Centre
mi
from 43215
Bedford Park,
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
492
mi
from 43215
Birmingham, AL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
1977
mi
from 43215
Long Beach, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
1977
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
1976
mi
from 43215
North Hollywood, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
1976
mi
from 43215
North Hollywood, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
1162
mi
from 43215
Denver, CO
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
996
mi
from 43215
Miami, FL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
279
mi
from 43215
Evansville, IN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
279
mi
from 43215
Evansville, IN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
213
mi
from 43215
Flint, MI
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
213
mi
from 43215
Flint, MI
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
662
mi
from 43215
Jackson, MS
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
662
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
342
mi
from 43215
Asheboro, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
342
mi
from 43215
Asheboro, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
348
mi
from 43215
Charlotte, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
837
mi
from 43215
Fargo, ND
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
837
mi
from 43215
Fargo, ND
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
1
mi
from 43215
Columbus, OH
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
849
mi
from 43215
Oklahoma City, OK
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
280
mi
from 43215
Knoxville, TN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
280
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
1700
mi
from 43215
Edmonton,
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
1700
mi
from 43215
Edmonton,
Click here to add this to my saved trials
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic
1650
mi
from 43215
Phoenix, AZ
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic
1650
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated:  1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
682
mi
from 43215
Omaha, NE
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated: 1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Status: Enrolling
Updated:  1/7/2016
Temple University Hospital
416
mi
from 43215
Philadelphia, PA
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Status: Enrolling
Updated: 1/7/2016
Temple University Hospital
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Status: Enrolling
Updated:  1/8/2016
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Status: Enrolling
Updated: 1/8/2016
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients
Status: Enrolling
Updated:  1/11/2016
Winthrop University Hospital
496
mi
from 43215
Mineola, NY
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients
Status: Enrolling
Updated: 1/11/2016
Winthrop University Hospital
496
mi
from 43215
Mineola, NY
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Arizona Health Sciences Center
1639
mi
from 43215
Tucson, AZ
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Arizona Health Sciences Center
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
National Jewish Health
1160
mi
from 43215
Denver, CO
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
National Jewish Health
1160
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Yale University
537
mi
from 43215
New Haven, CT
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Yale University
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Medical University of South Caolina
524
mi
from 43215
Charleston, SC
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Medical University of South Caolina
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Vanderbilt University
331
mi
from 43215
Nashville, TN
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Vanderbilt University
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Efficacy, Pharmacokinetics and Safety of Testosterone
A Phase 2 Open-label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes of Topical Testosterone in Hypogonadal Males
Status: Enrolling
Updated:  1/13/2016
Accumed Research Associates
496
mi
from 43215
Garden City, NY
Efficacy, Pharmacokinetics and Safety of Testosterone
A Phase 2 Open-label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes of Topical Testosterone in Hypogonadal Males
Status: Enrolling
Updated: 1/13/2016
Accumed Research Associates
496
mi
from 43215
Garden City, NY
Click here to add this to my saved trials
Exercise Dose Response for Improving Insulin Sensitivity
Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.
Status: Enrolling
Updated:  1/14/2016
Michigan Clincal Research Unit
167
mi
from 43215
Ann Arbor, MI
Exercise Dose Response for Improving Insulin Sensitivity
Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.
Status: Enrolling
Updated: 1/14/2016
Michigan Clincal Research Unit
167
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Status: Enrolling
Updated:  1/19/2016
UF and Shands Health
713
mi
from 43215
Gainesville, FL
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Status: Enrolling
Updated: 1/19/2016
UF and Shands Health
713
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
Status: Enrolling
Updated:  1/20/2016
Duke University Medical Center Dialysis Unit
351
mi
from 43215
Durham, NC
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
Status: Enrolling
Updated: 1/20/2016
Duke University Medical Center Dialysis Unit
351
mi
from 43215
Durham, NC
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
1980
mi
from 43215
Torrance, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
1980
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
ACTIV- Exercise Intervention in Healthy Young Men
"ACTIV"Validation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle
Status: Enrolling
Updated:  1/22/2016
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
ACTIV- Exercise Intervention in Healthy Young Men
"ACTIV"Validation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle
Status: Enrolling
Updated: 1/22/2016
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated:  1/25/2016
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated: 1/25/2016
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated:  1/25/2016
Kelsey-Seybold Clinics
991
mi
from 43215
Houston, TX
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated: 1/25/2016
Kelsey-Seybold Clinics
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated:  1/28/2016
University of Maryland
343
mi
from 43215
Baltimore, MD
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated: 1/28/2016
University of Maryland
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
Status: Enrolling
Updated:  1/28/2016
University of Pittsburgh, Montefiore Hospital
163
mi
from 43215
Pittsburgh, PA
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
Status: Enrolling
Updated: 1/28/2016
University of Pittsburgh, Montefiore Hospital
163
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Effects of Hesperidin on Insulin Sensitivity
An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects
Status: Enrolling
Updated:  1/28/2016
University of Maryland
343
mi
from 43215
Baltimore, MD
Effects of Hesperidin on Insulin Sensitivity
An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects
Status: Enrolling
Updated: 1/28/2016
University of Maryland
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Status: Enrolling
Updated:  2/1/2016
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Status: Enrolling
Updated: 2/1/2016
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Reciprocating Medical Devices - a Study of a New Safety Device
Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures
Status: Enrolling
Updated:  2/2/2016
University of New Mexico Health Sciences Center
1335
mi
from 43215
Albuquerque, NM
Reciprocating Medical Devices - a Study of a New Safety Device
Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures
Status: Enrolling
Updated: 2/2/2016
University of New Mexico Health Sciences Center
1335
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated:  2/2/2016
UCLA
1982
mi
from 43215
Los Angeles, CA
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated: 2/2/2016
UCLA
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated:  2/2/2016
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated: 2/2/2016
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery
Status: Enrolling
Updated:  2/2/2016
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery
Status: Enrolling
Updated: 2/2/2016
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes
Status: Enrolling
Updated:  2/4/2016
Purdue University
207
mi
from 43215
West Lafayette, IN
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes
Status: Enrolling
Updated: 2/4/2016
Purdue University
207
mi
from 43215
West Lafayette, IN
Click here to add this to my saved trials